The main purpose of this study is to assess the safety of three different doses of an investigational drug in patients who have been recently diagnosed with type 1 diabetes.
The investigational drug is a “therapeutic vaccine” and affects the body’s immune system response to a medical condition or disease. It is designed to stop the immune system from attacking cells that produce insulin, which may help insulin production in patients with recently diagnosed type 1 diabetes.
In this study, patients will receive 4 injections of the investigational drug over a period of 6 weeks. Total study participation will last approximately 24 weeks, which includes 8 study clinic visits for various tests and evaluations.
All study-related visits, tests, and drugs will be provided at no cost. In addition, reimbursement for study-related time and travel may be provided.
To pre-qualify for this study, you must:
- Be 18 to 30 years of age
- Have been diagnosed with type 1 diabetes in the last 6 months
- Have an insulin requirement
If you are interested in taking part please complete the Getting Involved form.